Risk Factors For Thromboembolism (Te) In Multiple Myeloma (Mm) Patients (Pts) Treated With Immunomodulatory Agents (Imids) Plus Dexamethasone (Dex)

Jai N. Patel,Megan Helena Jagosky,Myra M. Robinson,Daniel Slaughter,Justin Arnall,Ashley Matusz-Fisher,Manisha Bhutani,Peter M. Voorhees,Saad Z. Usmani

BLOOD（2018）

引用 0|浏览0

暂无评分

摘要

Introduction: MM pts have one of the highest risks of TE among cancer pts. Use of IMiDs plus dex further increases this risk. Guidelines recommend thromboprophylaxis based on risk assessment; however, limited large-scale studies have attempted to validate previous and identify new patient-specific risk factors associated with TE in MM pts.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要